Single-Use Systems Extend Much Broader Biopharma Coverage
Biopharma manufacturers increasingly specify single-use aseptic peristaltic pumps that deliver contamination-free transfer capacity standard mechanical seal pumps alone cannot support reliably across expanding single-use bioprocessing programmes, where sustained aseptic reliability matters more than the added pump cost single-use architecture introduces, with providers such as Watson-Marlow expanding single-use production capacity to meet rising specification demand across their growing customer base worldwide. Single-use segment demand grows about 19% of category revenue, and gross margins run 28% to 35% across the category. This trend continues accelerating through coming years across regulated biopharma manufacturing hubs in particular. considerably further.
Market Impact: contamination free priorities add 2-4% growth








